Format

Send to

Choose Destination
Vaccine. 2016 Feb 10;34(7):968-73. doi: 10.1016/j.vaccine.2015.12.046. Epub 2016 Jan 4.

Maternal Tdap vaccination: Coverage and acute safety outcomes in the vaccine safety datalink, 2007-2013.

Author information

1
HealthPartners Institute for Education and Research, Minneapolis, MN, United States. Electronic address: Elyse.o.kharbanda@healthpartners.com.
2
HealthPartners Institute for Education and Research, Minneapolis, MN, United States.
3
Yale University School of Medicine, Department of Obstetrics, Gynecology, & Reproductive Sciences, New Haven, CT, United States.
4
Kaiser Permanente of Northern California, Oakland, CA, United States.
5
Kaiser Permanente of Southern California, Pasadena, CA, United States.
6
Kaiser Permanente Northwest, Portland, OR, United States.
7
Harvard Pilgrim Health Care Institute & Harvard Medical School, Boston, MA, United States.
8
Institute for Health Research, Kaiser Permanente Colorado and Department of Ambulatory Care Services, Denver Health, Denver, CO, United States.
9
Group Health Cooperative, Seattle, WA, United States.
10
Kaiser Permanente Georgia, Atlanta, GA, United States.
11
Centers for Disease Control and Prevention, Atlanta, GA, United States.

Abstract

INTRODUCTION:

Since October 2012, the combined tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine (Tdap) has been recommended in the United States during every pregnancy.

METHODS:

In this observational study from the Vaccine Safety Datalink, we describe receipt of Tdap during pregnancy among insured women with live births across seven health systems. Using a retrospective matched cohort, we evaluated risks for selected medically attended adverse events in pregnant women, occurring within 42 days of vaccination. Using a generalized estimating equation, we calculated adjusted incident rate ratios (AIRR).

RESULTS:

Our vaccine coverage cohort included 438,487 live births between January 1, 2007 and November 15, 2013. Across the coverage cohort, 14% received Tdap during pregnancy. By 2013, Tdap was administered during pregnancy in 41.7% of live births, primarily in the 3rd trimester. Our vaccine safety cohort included 53,885 vaccinated and 109,253 matched unvaccinated pregnant women. There was no increased risk for a composite outcome of medically attended acute adverse events within 3 days of vaccination. Similarly, across the safety cohort, over a 42 day window, incident neurologic events, thrombotic events, and new onset proteinuria did not differ by maternal receipt of Tdap. Among women receiving Tdap at 20 weeks gestation or later, as compared to their matched controls, there was no increased risk for gestational diabetes or cardiac events while venous thromboembolic events and thrombocytopenia were diagnosed within 42 days of vaccination at slightly decreased rates.

CONCLUSION:

Tdap coverage during pregnancy increased from 2007 through 2013, but was still below 50%. No acute maternal safety signals were detected in this large cohort.

KEYWORDS:

Maternal vaccination; Tdap; Vaccine coverage; Vaccine safety

PMID:
26765288
PMCID:
PMC6506839
DOI:
10.1016/j.vaccine.2015.12.046
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center